Global Duchenne Muscular Dystrophy Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Route of Administration;

Oral and Injectable.

By Therapy Type;

Molecular-Based Therapies - Mutation Suppression and Exon Skipping, Steroid Therapy - Corticosteroids, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), and Others.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn371786367 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Duchenne Muscular Dystrophy Therapeutics Market (USD Million), 2021 - 2031

In the year 2024, the Global Duchenne Muscular Dystrophy Therapeutics Market was valued at USD 17,538.12 million. The size of this market is expected to increase to USD 133,238.08 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 33.6%.

The COVID-19 pandemic had a profound impact on the Duchenne muscular dystrophy (DMD) market, with the incidence rate of DMD reportedly increasing during the outbreak. Individuals with neuromuscular abnormalities, such as DMD, were deemed at higher risk for severe COVID-19 symptoms, particularly if they had underlying cardiac or respiratory issues. This heightened risk prompted a surge in treatment adoption rates for DMD patients, as mitigating the risk of COVID-19 complications became paramount. Consequently, the market witnessed significant growth during the pandemic period, driven by the increased demand for DMD treatments to address both the disease itself and potential COVID-19-related complications.

The rising burden of Duchenne muscular dystrophy, coupled with increasing investments in research and development, are key drivers propelling market growth. The prevalence of DMD globally has been on the rise, with notable figures reported in various studies and research articles. Additionally, both public and private sectors have ramped up investments in R&D efforts, leading to a surge in clinical trials aimed at evaluating potential therapies for DMD. This heightened focus on research has spurred the discovery and development of pharmaceutical drugs, with many major companies dedicating resources to this endeavor.

The emergence of mutation-specific therapies represents a significant breakthrough in DMD treatment. The development of these therapies, along with increasing awareness campaigns and the introduction of novel medications like Exondys51 and Translarna, has positively influenced market dynamics. Additionally, significant support from various firms for drug research, coupled with advocacy from patient groups, has facilitated the regulatory approval process and accelerated the introduction of new therapies.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Route of Administration
    2. Market Snapshot, By Therapy Type
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Duchenne Muscular Dystrophy Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Disease Burden and Prevalence
        2. Growing Investment in Research and Development
        3. Supportive Regulatory Environment and Orphan Drug Designation
      2. Restraints
        1. Limited Treatment Options
        2. High Cost of Treatment
        3. Challenges in Drug Development
      3. Opportunities
        1. Expansion of Steroid Therapies
        2. Emerging Targeted Therapies
        3. Expansion into Adjacent Therapeutic Areas
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Duchenne Muscular Dystrophy Therapeutics Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Injectable
    2. Global Duchenne Muscular Dystrophy Therapeutics Market, By Therapy Type, 2021 - 2031 (USD Million)
      1. Molecular-Based Therapies
        1. Mutation Suppression
        2. Exon Skipping
      2. Steroid Therapy
        1. Corticosteroids
      3. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
      4. Others
    3. Global Duchenne Muscular Dystrophy Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Global Duchenne Muscular Dystrophy Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Bristol-Myers Squibb
      2. BioMarin
      3. Fibrogen Inc
      4. Nobelpharma Co Ltd
      5. NS Pharma Inc
      6. Pfizer Inc
      7. PTC Therapeutics
      8. Santhera Pharmaceuticals
      9. Sarepta Therapeutics
      10. Eli Lilly and Company
  7. Analyst Views
  8. Future Outlook of the Market